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ABSTRACT
Drug concentrations in cerebrospinal fluid (CSF) are typically used as a as a surrogate measure of their availability in 
the CNS, and CSF penetration in animal studies are used for assessment of CNS drug delivery in early preclinical drug 
development. The minipig is a valid alternative to dogs and non-human primates as non-rodent species in preclinical 
research, but this species presents anatomical peculiarities that make the serial collection of CSF technically challenging. 
A minimally-invasive serial cerebrospinal fluid collection model via catheterization of the subarachnoid space in conscious 
minipigs was developed allowing assessment of longitudinal drug pharmacokinetics in the central nervous system in 
preclinical research. Shortly, the subarachnoid space was accessed in the anesthetized minipig by puncture with a Tuohy 
needle; when CSF was flowing through the needle a catheter was advanced and thereafter tunneled and fixed on the 
back. The PK of peptide A administered subcutaneously was performed and CSF could be sampled in the conscious 
animals for up to 48 h. When compared to the plasma kinetic data, there was a clear difference in the elimination phase 
of Pept. A from CSF, with an apparent longer average terminal half-life in CSF. The 3Rs are addressed by reducing the 
number of animals needed for a pharmacokinetic profile in central nervous system and by improving the validity of the 
model avoiding biases due to anesthesia, blood contamination, and inter-individual variability.
Keywords: CSF collection, Göttingen minipig, in vivo study, longitudinal CSF PK study, minimally-invasive model
INTRODUCTION
In central nervous system (CNS) drug research, drug concentrations 
in cerebrospinal fluid (CSF) are typically considered a good surrogate of 
concentrations at pharmacological target site e.g., the brain interstitial 
fluid (ISF), and are therefore used for pharmacokinetic/pharmacody-
namics relationship assessment in both preclinical and clinical phases 
[1-3]. For drug candidates showing very low passive membrane per-
meability, e.g., small CNS peptide analogues, their concentration and 
respective kinetic profile in brain and CSF cannot be predicted from 
their unbound plasma PK profile, neither from in vitro data, and must 
be obtained from in vivo animal studies. As first, rodent models are used 
and subsequently translated to larger animals. CSF can be sampled at 
the cerebral ventricles (CV), cisterna magna (CM) or lumbar thecal 
sites in conscious or anesthetized animals [4-6]. To perform a full PK 
profile of a compound in CNS, multiple CSF sampling time points are 
needed. Acute CSF models, with repeated puncturing with or without 
anesthesia or after euthanasia require a large number of animals for 
accommodating all time points, thereby posing a challenge to adhere to 
3Rs and increasing inter-individual variability. Repeated puncturing is 
stressful for the conscious animal; manual puncture can result in blood 
vessel/tissue damage and consequent CSF contamination with blood 
as anesthesia can bias the experimental results. Chronic CSF sampling 
models try to circumvent these disadvantages by surgical implantation 
of a catheter into the brain or the lumbosacral space and bear the advan-
tages of allowing repeated sampling of CSF in conscious, freely moving 
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animals [7]. The minipig has become a valid alternative to dogs and 
non-human primates as non-rodent species in preclinical research [8,9]. 
Pigs have a stiff spine, massive vertebral bone structure with narrow 
intervertebral spaces (IVS), with the dorsal processes of the vertebrae 
tending to interfere with access to the IVS and a large bulk of epidural 
adipose tissue. These anatomical peculiarities make the serial collection 
of CSF technically challenging. In pigs, CSF is typically sampled from 
the CM [10], the CV [11] or via lumbar puncture under anesthesia or 
after euthanasia, with all disadvantages listed above. Spinal catheters 
for CSF collection could also be placed surgically by laminectomy [12]. 
Still this is invasive and requires advanced surgical skills that might not 
be available in each institution. We hypothesized that the listed tech-
nical limitations for CSF collection could be overcome by developing 
a minimally-invasive method via catheterization of the subarachnoid 
space allowing for serial CSF collection in conscious minipigs. The 
aim for the study presented was both to describe a minimally invasive 
method for CSF sampling through catheterization of the subarachnoid 
space and to validate this method within a pharmacokinetic study for 
a compound under investigation as therapeutic agent in CNS related 
disorders.
MATERIALS AND METHODS
Animals
All animals were Göttingen Minipigs purchased at Ellegaard Göt-
tingen Minipigs A/S, Dalmose, Denmark (n = 3, female, aged 25–37 
months, BW 43.7–52.2 kg). Animals were individually housed in an 
Association for Assessment and Accreditation of Laboratory Animal Care 
International (AAALACi) accredited facility with olfactory, visual, and 
auditory contact to their conspecifics in pens sized 8.6 m2, under a 12 h 
light, 12 h dark cycle. The environment was temperature-controlled (18°C 
± 2°C) with relative humidity ranging from 40%–80%. Animals were 
offered commercially available laboratory swine diet (Provimi-Kliba, 
Kaiseraugst, Switzerland) twice a day and tap water ad libitum. Apart 
from a straw box for each animal, enrichment devices (chewing toys, 
balls, kongs) were offered on a rotational basis. All animals underwent 
an acclimatization phase of at least three weeks before study start.
Use of experimental animals
The experimental protocol was approved by the cantonal veterinary 
authorities (Basel City) and all experiments performed according to the 
Swiss regulations and as described in the permission.
Intraoperative anesthesia, analgesia, and monitoring
For catheterization, anesthesia was induced by using 8% sevoflurane 
(Sevorane®, AbbVie AG, Baar, Switzerland) with a flow of 2 L/min (1:1 
air/O2) administered via a leak proof face mask, using a Matrx VMS
® 
anesthesia machine with a circle breathing system and a Tec7 Sevo-
flurane vaporizer. As soon as consciousness was lost, sevoflurane was 
reduced to 2%–4% and the carrier gas flow was set to 0.5–1 L/min (air/
O2 = 50%/50%) for the duration of catheterization. A local anesthetic 
was injected subcutaneously (0.5 ml Lidocain 2%, Streuli Pharma AG, 
Uznach, Switzerland) at the insertion site to guarantee perioperative 
analgesia. Animals were covered with the warming blanket of a forced 
air warming device (Bair hugger® model 750, 3M Switzerland Ltd., 
Rüschlikon, Switzerland) to ensure temperature close to the physiologic 
body temperature of 37°C–38°C in conscious Gottingen minipigs [13]. 
Eye ointment (Bepanthen®, Bayer AG, Zürich, Switzerland) was ap-
plied over the cornea to avoid desiccation. Heart rate (HR) and oxygen 
saturation of blood (SpO2) were continuously monitored via a pulse 
oximeter (Nonin Palm® Model SAT 2500A Vet, Nonin Medical B.V. 
Europe, Amsterdam, Netherlands) in addition to rectal body temperature.
Preparation
Animals were placed in either sternal or lateral recumbency, with 
the hind limbs stretched cranially in order to widen the IVS (Fig. 1A). 
The IVS cranial to the last lumbar vertebra was chosen as insertion 
point and was identified with anatomical landmarks (Fig. 1B). Briefly, 
the two tubera coxae were palpated and marked with a waterproof 
marker. The lumbosacral intervertebral space was identified just caudal 
to an imaginary line drawn between both tubera coxae, indicated by 
a depression in the spinous processes. All spinous processes and IVS 
cranial to the last lumbar vertebra were marked. These landmarks are 
valuable for identifying the targeted IVS without imaging techniques or 
when using pigs with a higher amount of fatty tissue. The lumbar area 
was clipped and thoroughly washed and disinfected with iodine soap 
(Betadine® soap, Mundipharma Medical Company, Basel, Switzerland). 
The skin was sprayed with alcoholic iodine solution (Betaseptic®, 
Mundipharma Medical Company, Basel, Switzerland) and covered in 
sterile self-adhesive surgical drapes (Foliodrape®, IVF Hartmann AG, 
Neuhausen, Switzerland) (Fig. 1C).
Spinal catheterization
Catheterization was performed under aseptic conditions. An incision 
of about 5 mm was made in the skin above the intervertebral space 
cranial to the last lumbar vertebra with a disposable scalpel (#11, 
B.Braun, Aesculap AG, Tuttlingen, Germany) (Fig. 1D). An epidural 
needle (Perican® Needle with Tuohy bevel, 18 G 1.3 × 80 mm; part 
of the Perifix® 421 epidural anesthesia set, B. Braun Medical AG, 
Sempach, Switzerland) (Fig. 1E) was advanced with a ventro-crani-
al orientation forming an angle of 45° with the spinal cord through 
the skin, subcutaneous tissue, and interspinous ligament towards the 
subarachnoid space (Fig. 1F-1G). Entry into the epidural space was 
determined using either the loss-of-resistance (LOR) technique or the 
hanging drop (HD) technique. With the HD technique, the needle was 
filled with sterile saline and advanced until an inward movement of 
the saline was observed, as sign of the negative pressure present in the 
epidural space. With the LOR technique, a syringe filled with air was 
attached to the epidural needle, and loss of resistance to injection of air 
was examined intermittently while slowly advancing the needle, with 
clear loss of resistance identifying the epidural space. The needle was 
then carefully advanced further 5–10 mm into the subarachnoid space 
until CSF backflow was seen, indicating correct intrathecal positioning 
(Fig. 1H). Thereafter the stylet was removed and the epidural catheter 
(Perifix® ONE, part of the described set) was fed through the epidur-
al needle and gently advanced cranially in the subarachnoid space. 
Segmental markings on the catheter allowed determining that its tip 
was advanced approximately 8 cm into the subarachnoid space (Fig. 
1I). This length was chosen to place the catheter at the level of the 1st 
lumbar vertebra for study related sampling. Patency of the catheter was 
assessed by viewing the free CSF flow. The external part of the catheter 
was tunneled subcutaneously to add stability by using a small trocar to 
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exit around 6 cm cranial to the insertion point (Fig. 1J). The external 
tip of the catheter was connected to Snap catheter connector (part of 
the described Perifix® set). The skin incisions made prior to entry of 
the needle and for tunneling were adapted using non-absorbable mono-
filament suture material (Prolene® 3-0, Johnson & Johnson Medical, 
Spreitenbach, Switzerland). Thereafter the catheter was covered with 
gauze compresses then both, catheter and compresses were sutured to 
the skin (Fig. 1K).
Figure 1. Procedure of catheterization of the subarachnoid space. A. Positioning of the anesthetized minipig in sternal recumbency, with the hind 
limbs stretched cranially; B. Highlighting of anatomical landmarks with each black dot representing the IVS; C. Aseptic preparation of surgical field and 
draping; D. Initial skin incision; E. Epidural needle with Tuohy bevel; F. Orientation and angle of epidural needle; G. Advancement of epidural needle 
(hanging drop technique); H. Free flow of CSF; I. Insertion of catheter through epidural needle; J. Subcutaneous tunneling of the catheter; K. Catheter 
with the closed sampling port and gauze compresses sutured to skin; L. Minipig after recovery from anesthesia with CSF catheter on the back.
Recovery and post-catheterization monitoring
Post-catheterization, sevoflurane administration was discontinued 
and the animals were visually supervised until recovery (Fig. 1L). 
Extrapolating from man the expected intensity of pain for this inter-
vention, no post interventional analgesia was given. The minipigs were 
visually checked twice daily for integrity of the protective dressing and 
catheter and wellbeing. Action and endpoints were defined based on 
the recognition of clinical signs indicative of spinal cord impairment, 
neurologic deficit, pain or infection, and animals were monitored for 
48 h post-catheterization using the clinical scoring system (Table 1). 
Depending on the severity, intervention consisted either in close moni-
toring for up to 48 h if signs did not get worse or cutoff with euthanasia.
CSF sampling
The first CSF sampling began 24 h after catheter placement. At 
each time point, CSF was collected in two aliquots (100 µl each) under 
clean conditions by plunging the Snap connector with a sterile syringe 
and then applying gentle suction. The first sample withdrawn of CSF 
remaining in the catheter dead space was discarded. Sampling occurred 
in the home pen, restraining the minipig against one wall.
Pharmacokinetic study design
Catheterization (n = 3) was performed on the day before the lon-
gitudinal CSF PK study (Fig. 2) as described above. Pept. A, a highly 
hydrophilic cyclic small peptide with a molecular weight (MW) of 
about 1 kDa, was administered twice at 4.2 mg/kg subcutaneously 
on study day 1 and again on study day 2, with a dosing interval cor-
responding to 24 h. Based on results of previous pharmacokinetic 
studies in rats, Pept. A was known to be able to reach the CSF after 
peripheral administration. Blood (100 µl) and CSF (100 µl) aliquots for 
drug concentration assessment were collected pre-dose, on study day 
1 at 0.5, 1.5, 3, 6, and 24 h post first dose, and on study day 2 at 1.5 h 
post the second dose (corresponding to 25.5 h from study start) (Fig. 
2). All blood samples were collected via microsampling (Microvette 
100K3E, Sarstedt AG&Co, Nümbrecht, Germany) from the lateral ear 
vein because blood sampling from the jugular vein would have required 
placing the animals on their backs and thereby potentially compromis-
ing the patency of the CSF catheters. CSF was sampled as described 
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above. On Study day 2, last samples collection was performed 1.5 h 
after the second administration of Pept. A (Fig. 2). Thereafter, animals 
were euthanized under anesthesia [8% sevoflurane (Sevorane®, AbbVie 
AG, Baar, Switzerland) by intravenous administration of an overdose of 
pentobarbital (120 mg/kg, Esconarkon®, Streuli Pharma AG, Uznach, 
Switzerland]. Gross and histopathological examination of the spine 
was performed to confirm the position of the catheter and evaluate 
potential changes of the spine. Samples were fixed in 10% buffered 
formalin (BioGnost d.o.o., Zagreb, Croatia), routinely embedded in 
paraffin (VIP® 5, Sysmex, Horgen, Switzerland; Tissue-Tek® TEC™ 5, 
Sakura Finetek Germany GmbH, Staufen, Germany), and 5 µm slides 
sections were cut (Microtome HM 350 S, Microm International GmbH, 
Walldorf, Germany) and deparaffinised, and routinely stained with he-
matoxylin eosin stain (Continous line stainer COT20, Medite GmbH, 
Burgdorf, Switzerland). EDTA-containing plasma was prepared from 
the collected blood samples by centrifugation; both CSF and plasma 
were stored at −20°C until bioanalysis. Bioanalytical assessment of 
Pept. A concentration in plasma and CSF matrices was performed by 
Liquid chromatography–mass spectrometry (LC-MS/MS).
Figure 2. PK study layout. Pept. A was administered subcutaneously to three CSF catheterized animals.
In brief, the quantification of Pept. A levels in plasma and CSF was 
accomplished by means of LC MS/MS. Plasma and CSF were pre-
cipitated in four volumes of a mix of Ethanol and Acetonitrile (50:50 
v/v) containing Bosentan (50 ng/ml) as internal standard, mixed and 
centrifuged (10 min, 3°C, 5889 g). Thereafter, 50 µl of the supernatant 
was diluted 50:50 on-line with [90% H2O + 9.8% Methanol + 0.2% 
Formic Acid v/v/v], then injected onto a Hypersil Gold 5 µM 10 × 2.1 
mm Javelin Guards column washed with [90% H2O + 9.8% Methanol 
+ 0.2% Formic Acid v/v/v] at 900 µl/min flow rate. After 48 s, the an-
alyte and the internal standard were transferred on a Supelco Ascentis 
Express C18 2.1 × 20 mm 2.7 µM operating with mobile phase [H2O 
+ Acetonitrile + Formic Acid v/v/v] at 600 µl/min flow rate. The outlet 
of the column was coupled to AB Sciex Qtrap 5500 mass spectrometer 
with TurboIonSpray source. Detection was carried out using multiple 
reactions monitoring mode with positive ion detection focusing in the 
transitions 989.26/687.20 for Pept. A.
Due to the small animal number, no statistical analysis was performed, 
but data were presented as mean values with standard deviation (SD) and 
coefficient of variation (CV%) calculated using Microsoft Excel 2010.
RESULTS
Catheterization (n = 3) was performed on the day before the lon-
gitudinal CSF PK study (Fig. 2): Anesthesia was uneventful with HR 
between 52 and 88 beats per minute (BPM) for subject #220613 and 
102 to 110 BPM for subject #222445, SpO2 was stable between 95 and 
100% for both animals, and sevoflurane was kept at 4 Vol% for both 
animals. The anesthesia record of subject #219514 was missing.
The landmark based identification of the subarachnoid space was 
the most delicate part of the procedure. A maximum of 3 attempts were 
allowed for identifying the subarachnoid space or if blood was noticed. 
In this case the procedure was aborted and the minipig recovered. When 
the subarachnoid placement was confirmed by free flow of CSF in the 
epidural needle, the catheter could be advanced cranially very smoothly, 
and the free retrograde flow of CSF in the catheter was immediately 
visible. Typically, it took between 35 and 50 min for the intervention for 
catheter placement, counting from anesthesia induction until stopping 
sevoflurane administration.
Recovery from anesthesia was smooth and animals returned to 
their normal behavior and activities within 1h after recovery (Fig. 1). 
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Serial CSF could be sampled in the conscious animals with minimal 
or no restraint; the samples were clear and transparent, thus not visibly 
contaminated with blood.
On study day 1 (24 h after catheter placement), subject #220613 
showed mild monolateral ataxia of the right hind limb, without reaching 
cutoff criteria. Details of the pathological changes in the symptomatic 
minipig are shown in Figure 3 and are explained by the insertion of the 
catheter in the spinal parenchyma distal to the insertion point. No gross 
and histopathological findings were present in the spinal cord of the two 
asymptomatic minipigs and their catheters were positioned dorsally.
Figure 3. Pathological findings in subject #220613 with clinical signs. A. Spinal cord with insertion of catheter into parenchyma (black arrow) and 
cranial to the insertion dorsal presence of catheter (white arrows); B. Imprint of catheter (asterisk) and focal acute hemorrhage with associated spheroids 
(axonal degeneration) in ventrolateral region, black arrow points to region of degeneration; C. Higher magnification of (B) with hemorrhage and axonal 
degeneration; D. Lumbar spinal cord cranial to the insertion of the catheter, small imprint on dorsal spinal cord without parenchymal reaction (white 
arrow); considered secondary to fixation of tissue with catheter; E. Higher magnification of (D).
The compound tested in the PK validation study was a small cy-
clic peptide with a MW of ca. 1 kDa, here named “Pept. A”, under 
investigation as therapeutic agent against a CNS-related disorder. 
Due to company policy and restrictions on disclosure of confidential 
information, its molecular structure and target cannot be reported 
here. The plasma and CSF concentrations and PK data are reported in 
Figure 4 and in Table 2 and Table S1. Pept. A was rapidly distributed 
in the circulation after SC injection, with an average Tmax of 0.5 h 
and short (3.5 h) derived average terminal half-life. In CSF, Pept. A 
concentration was above the lowest detection limit (> 10 ng/ml) until 
24 h post first dose. When compared to the plasma kinetic data, there 
was a clear difference in the elimination phase of Pept. A from CSF, 
with an apparent longer average terminal half-life in CSF in agreement 
with previous observations in rats and estimated to be driven by the 
CSF flow rate. Regarding the uptake of Pept. A in the brain (CSF) from 
the circulation, an average AUC0-24CSF/plasma value of ca. 2% was 
calculated, explained by the limited passive permeability of the peptide 
and its hydrophilic nature. Despite of similar PK profiles obtained 
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in plasma between animals, subject #220613 showed a remarkably 
higher Pept. A exposure in CSF. This observation could not be further 
explored in a follow-up work, but was considered to be related to the 
intactness of the Blood-Brain-Barrier or Blood-CSF-Barrier, likely 
lower in this animal, and/or to a more efficient active brain uptake of 
Pept. A. Finally, the exposure of Pept. A in the CSF at 1.5 h after the 
second dosing obtained from lumbar catheterization and choroid plexus 
(CP) sampling was comparable, indicating a homogenous distribution 
of the test compound in the CSF (Table 2).
Figure 4. Concentration profile of Pept. A in CSF and plasma obtained from longitudinal sampling in minipigs after the first subcutaneous dose. A. 
Individual concentrations of Pept. A in plasma; B. Individual concentrations of Pept. A in CSF; C. Average (SD) concentrations of Pept. A in plasma and 
CSF The lower limit of quantification is also displayed.
DISCUSSION
To the best of our knowledge this is the first description of mini-
mally-invasive serial CSF sampling in conscious minipigs. The IVS 
cranial to the last lumbar vertebra was chosen for needle insertion, as 
it is the largest facilitating access [14]. When defining the anatomical 
landmarks, it has to be kept in mind that minipigs have a varying 
number of lumbar vertebrae (L5–L6) [14]; we recommend orientating 
from the lumbosacral IVS in cranial direction. Also the caudal IVS 
was chosen to reduce the risk of iatrogenic lesions to the spinal cord. 
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Nevertheless, the conus medullaris in minipigs, as observed from the 
gross pathology, extends to sacral vertebra S2–S3 [15], making the risk 
for iatrogenic lesions higher than in other species. Strict adherence to 
standard technique for localizing the epidural space (loss of resistance 
or hanging drop) followed by advancing the needle 5 mm deeper is 
essential for a correct targeting of the dorsal subarachnoid space and 
avoidance of spinal cord damage. Intervertebral ligaments in swine 
are highly resistant hindering smooth insertion. The major technical 
limit remains the reliable identification and atraumatic access to the 
subarachnoid space. Prospectively the use of imaging techniques such 
as ultrasound, fluoroscopy or CT to improve the localization of the 
epidural and subarachnoid space should be investigated, enhancing 
success rate and safety.
Table 1. Action and end point criteria. 
Symptoms Decision Actions
Paresis or mild ataxia of the hind limbs, mono- or bilateral
• Minipigs are able to walk, but are weak and wobbly in the rear legs. 
They may cross their back legs when walking, splay out, knuckle over 
or stumble in their back legs.
• Bladder and intestinal function is maintained.
Acceptable for max 48 h Monitoring
Worsening of paresis to paralysis or from monolateral to bilateral
• Minipigs are still able to move their legs and wag their tails, but not 
strong enough to support its own weight and walk.
• Bladder and intestinal function is maintained but need to be supported.
Cut off Euthanasia
Pain or fever
• Shivering, crying, muscle spasms, and/or a tense abdomen
Cut off Removal of the spinal catheter and systemic 
treatment (antibiotics and analgesics)
Table 2. Average PK parameters ± SD (CV%) for Pept. A estimated in minipig plasma and CSF. 
aPK parameters of Pept. A after SC administration based 
on plasma or CFS concentration data
Units Plasma mean ± SD 
(CV%)
CSF lumbar mean ± SD 
(CV%)
CSF CP
Apparent terminal half-life (T1/2) h 3.5 ± 0.7 (21%)  14.3 ± 5.5 (40%) -
Tmax h 0.5 3.0 -
Cmax ng/ml 4683 ± 340 (7.2%) 35.8 ± 19 (54.7%) -
AUC0-24 h*ng/ml 20970 ± 4820 (23%) 445 ± 244 (55%) -
AUC0-24 CSF/plasma ratio % - 2.1 -
Mean Concentration at 25.5 h (1.5 h after the second dose) ng/ml 4020 ± 643 (16%) 38.1 ± 18 (49%) 48.0b
CSF/plasma concentration ratio at 25.5 h (1.5 h after the 
second dose)
% - 0.9 (range 0.4–1.5) 1.2
aPK parameters were estimated by non-compartmental analysis using CSF and plasma concentration data (n = 3 animals) with Phoenix 64. bThese data 
are from only one animal as the CSF sample collected from the other two subjects was visibly contaminated with blood, thus not usable. Data from Roche 
Study No. EX16_401380.
The rationale for selecting an off-label epidural catheter instead of 
a spinal catheter was based on the larger lumen facilitating retrieval 
of CSF; spinal catheters of the necessary size are not commercially 
available. Another important technical feature of the chosen epidural 
catheter is its 3 lateral openings avoiding adhesion of its tip to the 
arachnoid membranes and consequent occlusion while sampling. The 
use of a large catheter in the narrow spines can lead to compression of 
the spinal cord clinically resulting in neurological deficits as observed 
in one animal (Fig. 3); therefore, the smallest size of epidural catheter 
allowing free flow of CSF should be selected.
Sevoflurane was chosen for anesthesia as it is safe and well tolerated 
in pigs for mask induction [16] and also for its favorable pharmacokinetic 
profile [17], with minimal metabolism and accumulation in fat which 
is proportional to the length of anesthesia. Based on these properties, 
the short anesthesia duration for the instrumentation, the 24 h wash-out 
period before first dosing and sampling in conscious animals, we did 
not expect any influence of the anesthetic on kinetics of the compound 
under investigation. This was a rationale in developing the model and 
its strength.
From previous in vitro essays (data not shown), it was known that 
Pept. A displayed a very low membrane passive permeability (below 
quantification) as well as no binding to plasma proteins. In rodents, 
systemic clearance of Pept. A was very high as expected due to the nature 
of the molecule, resulting in a very short terminal half-life in plasma 
< 0.5 h. The compound quickly reached the CSF after subcutaneous 
dosing and the kinetic in CSF was clearly different from those observed 
in plasma, suggesting that the plasma kinetic data of Pept. A could not 
be used to predict its exposure in the brain, and that measurements of 
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longitudinal CSF PK profile in large animals were needed to progress the 
project into clinical trials. In minipigs, Pept. A was rapidly distributed 
in the circulation after SC injection, in line with the expectations for a 
small peptide showing no binding to plasma proteins, and aligned with 
previous PK data acquired in rodents. Regarding the uptake of Pept. 
A in the brain (CSF) from the circulation, the very low AUC0-24CSF/
plasma value was aligned with data from previous rodent PK studies 
(AUC0-24CSF/plasma 1%–1.5%) where a CSF sample was collected at 
animal termination from CP site, increasing the confidence of human 
CSF PK translations.
In conclusion, we have described a new method refining serial CSF 
sampling in conscious minipigs. This technique is highly valuable for 
measuring the longitudinal CNS PK profile of drug candidates targeting 
the brain as it allows minimally-invasive determination of drug concen-
tration at target site (CSF) in a time-dependent manner from the same 
animal. The availability of compound concentration kinetic at target 
site is essential for understanding the pharmacodynamic effect, for 
enabling drug candidate optimization and selection, and for allowing 
extrapolation of preclinical PK/PD data to human during early drug 
research phases. The described methodology reduces the number of 
animals, enhances PK data reliability by excluding inter-individual 
differences compared to a composite PK profile, and avoids technical 
biases of anesthesia or blood contamination. Although the approach is 
technically challenging, it is minimally invasive and well tolerated by 
the minipigs without disturbing their normal behavior. Overall it can 
be concluded that the 3Rs concept was successfully addressed and 
animal welfare improved.
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